CHU Dijon Bourgogne Hôpital François Mitterand

Dijon 9 trials 6 recruiting

9 Registered trials

6 Currently recruiting

Organisation

CHU Dijon Bourgogne Hôpital François Mitterand

Location

Dijon, France

Identifier

ORL-000002076

Address

14 rue Gaffarel, 21000, France

Departments

Endocrinologie, Diabétologie, Maladies Métaboliques et Nutrition
Hematology
Hepato-gastroenterology and Digestive oncology
Maladies infectieuses
ONCOLOGIE
Oncology
Oncology for pediatrics
Pneumology
Service Immuno-Hématologie Oncologie Pédiatrique

Clinical trials at this site (9)

Search interface

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents Pending

2024-514243-29-01 This is a prospective, French, multicenter, open-label, 5
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial Recruiting

2024-516789-13-00 Severe asthma 6 2025-12-15
Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 … Recruiting

2023-508634-34-00 co-infected with the HIV-1 and HBV viruses 4 2025-05-14
EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib… Recruiting

2023-505330-95-01 Blood cancer 4 2025-01-30
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Patients with High Risk Neuroblastoma 5 2024-11-21
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder. Ended

2023-506511-17-00 Binge eating disorder 4 2022-03-07
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 stomach cancer 4